The DURYSTA market potential seems strong due to the increasing prevalence of glaucoma, the need for long-term, non-adherence-dependent treatments, and its advantage over daily eye drops. With an ...
Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback